The document summarizes key information about HIV and AIDS, including:
- HIV infects and replicates within CD4 immune cells, weakening the immune system and potentially causing AIDS.
- HIV progresses through three main phases: asymptomatic, symptomatic, and AIDS. It is transmitted through bodily fluids and can be tested for through antibody and viral load tests.
- While there is no cure for HIV/AIDS, treatment involves antiretroviral drugs that target different stages of the HIV lifecycle to suppress viral replication and slow disease progression.
HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom or HIV medicine to prevent or treat HIV), or through sharing injection drug equipment.
Seasonal influenza (the flu) is an acute respiratory infection caused by influenza viruses. It is common in all parts of the world. Most people recover without treatment.
Influenza spreads easily between people when they cough or sneeze. Vaccination is the best way to prevent the disease.
Symptoms of influenza include acute onset of fever, cough, sore throat, body aches and fatigue.
Treatment should aim to relieve symptoms. People with the flu should rest and drink plenty of liquids. Most people will recover on their own within a week. Medical care may be needed in severe cases and for people with risk factors.
There are 4 types of influenza viruses, types A, B, C and D. Influenza A and B viruses circulate and cause seasonal epidemics of disease.
Influenza A viruses are further classified into subtypes according to the combinations of the proteins on the surface of the virus. Currently circulating in humans are subtype A(H1N1) and A(H3N2) influenza viruses. The A(H1N1) is also written as A(H1N1)pdm09 as it caused the pandemic in 2009 and replaced the previous A(H1N1) virus which had circulated prior to 2009. Only influenza type A viruses are known to have caused pandemics.
Influenza B viruses are not classified into subtypes but can be broken down into lineages. Influenza type B viruses belong to either B/Yamagata or B/Victoria lineage.
Influenza C virus is detected less frequently and usually causes mild infections, thus does not present public health importance.
Influenza D viruses primarily affect cattle and are not known to infect or cause illness in people.
HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom or HIV medicine to prevent or treat HIV), or through sharing injection drug equipment.
Seasonal influenza (the flu) is an acute respiratory infection caused by influenza viruses. It is common in all parts of the world. Most people recover without treatment.
Influenza spreads easily between people when they cough or sneeze. Vaccination is the best way to prevent the disease.
Symptoms of influenza include acute onset of fever, cough, sore throat, body aches and fatigue.
Treatment should aim to relieve symptoms. People with the flu should rest and drink plenty of liquids. Most people will recover on their own within a week. Medical care may be needed in severe cases and for people with risk factors.
There are 4 types of influenza viruses, types A, B, C and D. Influenza A and B viruses circulate and cause seasonal epidemics of disease.
Influenza A viruses are further classified into subtypes according to the combinations of the proteins on the surface of the virus. Currently circulating in humans are subtype A(H1N1) and A(H3N2) influenza viruses. The A(H1N1) is also written as A(H1N1)pdm09 as it caused the pandemic in 2009 and replaced the previous A(H1N1) virus which had circulated prior to 2009. Only influenza type A viruses are known to have caused pandemics.
Influenza B viruses are not classified into subtypes but can be broken down into lineages. Influenza type B viruses belong to either B/Yamagata or B/Victoria lineage.
Influenza C virus is detected less frequently and usually causes mild infections, thus does not present public health importance.
Influenza D viruses primarily affect cattle and are not known to infect or cause illness in people.
H: Infects only Human beings
I: Immunodeficiency Virus weakness the Immune system and increases the risk of infections
V: Virus that attacks the body and finally kills the body’s immune system
H: Infects only Human beings
I: Immunodeficiency Virus weakness the Immune system and increases the risk of infections
V: Virus that attacks the body and finally kills the body’s immune system
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Antimicrobial stewardship to prevent antimicrobial resistanceGovindRankawat1
India is among the nations with the highest burden of bacterial infections.
India is one of the largest consumers of antibiotics worldwide.
India carries one of the largest burdens of drug‑resistant pathogens worldwide.
Highest burden of multidrug‑resistant tuberculosis,
Alarmingly high resistance among Gram‑negative and Gram‑positive bacteria even to newer antimicrobials such as carbapenems.
NDM‑1 ( New Delhi Metallo Beta lactamase 1, an enzyme which inactivates majority of Beta lactam antibiotics including carbapenems) was reported in 2008
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
7. Human Immunodeficiency Virus (HIV)- virus
that primarily infects cells of the immune
system and that causes AIDS
Acquired Immune Deficiency Syndrome
(AIDS)- disease that is caused by HIV
infection, which weakens the immune system
Pandemic- disease that spreads quickly
through human populations all over the world
8. HIV
“Human Immunodeficiency Virus”
A specific type of virus (a retrovirus)
HIV invades the helper T cells to
replicate itself.
10. AIDS
Acquired Immunodeficiency Syndrome
HIV is the virus that causes AIDS
Disease limits the body’s ability to fight
infection
A person with AIDS has a very weak
immune system
11. Chapter 21.2 Key Terms
Helper T Cell- white blood cell that activates
the immune response and that is the primary
target cell of HIV infection
Opportunistic Infection- illness due to an
organism that causes disease in people with
weakened immune systems; commonly found
in AIDS patients
Asymptomatic stage- infection in which the
infectious agent, such as HIV, is present but
there are few or no symptoms of the infection
12. HIV uses CD4 immune
cells to replicate. And
each infected CD4 cell
produces hundreds of
new copies of new
HIV particles. The
process is called the
HIV lifecycle. Each
replication cycle only
lasts 1 to 2 days.
13. When viruses reproduce it
is called replication. HIV
uses CD4 immune cells to
replicate. And each
infected CD4 cell produces
hundreds of new copies of
new HIV particles.
15. Phase 1- Asymptomatic Stage
Short, flu-like illness, swollen glands, fatigue,
diarrhea, weight loss, or fevers - occurs one to six
weeks after infection
no symptoms at all
Infected person can infect other people
Lasts for an average of ten years
HIV antibodies are detectable in the blood
17. Phase 3 - HIV AIDS
Immune system
weakens
Emergence of
opportunistic
infections
The illnesses
become more severe
leading to an AIDS
diagnosis
18. Opportunistic Infections
associated with AIDS
Bacterial
Tuberculosis (TB)
Pneumocystis
pneumonia
Viral
Kaposi Sarcoma-
purple-red blotches
on the skin
Influenza (flu)
19. The seven stages of the HIV life cycle
are: 1) binding, 2) fusion, 3)
reverse transcription, 4)
integration, 5) replication, 6)
assembly, and 7) budding.
20. HIV uses CD4 immune cells to replicate.
And each infected CD4 cell produces
hundreds of new copies of new HIV
particles. The process is called the HIV
lifecycle. Each replication cycle only
lasts 1 to 2 days.
22. The new double-stranded HIV can now
be integrated into human DNA. Drugs
that block this process are called
integrase inhibitors, abbreviated to INIs
or INSTIs.
23. The CD4 nucleus then starts producing
raw material to make new HIV. These
long strands of new HIV particles need
to be cut up and assembled as new
virus. The enzyme involved in the
cutting and assembling process is called
protease. The HIV meds that block this
process are called protease inhibitors.
24.
25. a fter HIV attaches to the CD4 cell, it is
absorbed into the main body of the cell. As
this happens, HIV first loses its outer shell.
This leaves viral capsid with HIV and three
key enzymes (a type of protein) that HIV
uses to replicate. The capsid releases its
contents into the cell nucleus.
26. These enzymes then work in the nucleus.
The first enzyme is called RT. This stands for
reverse transcriptase. RT changes the single
strand of HIV (called RNA) into a double
strand to fit in with human DNA. Two
different types of RT inhibitors (RTIs) block
this process: (i) nucleoside/tide
(NRTIs/NtRTIs), and (ii) non-nucleoside
(NNRTIs).
27. Through IV Drug Use
Sharing Needles
Without sterilization
Increases the chances of contracting HIV
30. Chapter 21.3 Key Terms
Universal Precautions- set of procedures used
to avoid contact with body fluids & to reduce
the risk of spreading HIV & other diseases
HIV-antibody test- detects HIV antibodies to
determine if a person has been infected with
HIV
HIV Positive- person who tests positive in 2
different HIV tests
Drug Combination Therapy- AIDS treatment
program in which patients regularly take
more than one drug
34. T cell count test
Shows the strength of a patient’s
immune system
This test can also tell whether a person
has developed AIDS
35. Viral load test
Measures of the number of viruses in
the blood
The higher the viral load, the more
infectious the person’s body fluids are
likely to be and the closer that person is
to having AIDS
37. Retest
Should be retested 6 months after the
first test
An initial negative test can be
misleading if the test is done too soon
after infection
40. newly formed virus then has to leave
the cell.
Budding inhibitors stop new HIV
from leaving of the CD4 cell.
Maturation inhibitors block the final
assembly process.
41. The newly released viruses (called
virions) go on to infect new CD4 cells –
to repeat the process over again. The
old CD4 cell then dies. This continuous
process happens millions of times every
day when not on ART. Without ART, HIV
is one of the most active and rapidly
reproducing virus.
42. Abbreviation Full names
NRTIs/NtRTIs
(“nukes”)
Nucleoside/tide reverse transcriptase inhibitors or
nucleoside/tide analogues.
NNRTIs (“non-
nukes”)
Non-nucleoside reverse transcriptase inhibitors.
PIs Protease inhibitors.
INIs (or INSTIs) Integrase (strand transfer) inhibitors.
CCR5 inhibitors CCR5 inhibitors are a type of entry inhibitor.
Fusion inhibitors Fusion inhibitors are a type of entry inhibitor.
mAbs Monoclonal antibodies block HIV entering the T-cell.
CIs (?) Capsid inhibitors.
L